PT  - JOURNAL ARTICLE
AU  - Yang, Fei
AU  - Wu, Yeda
AU  - Hockey, Richard
AU  - Doust, Jenny
AU  - Mishra, Gita D.
AU  - Montgomery, Grant W.
AU  - ,
AU  - Mortlock, Sally
TI  - Evidence of shared genetic factors in the aetiology of gastrointestinal disorders and endometriosis and clinical implications for disease management
AID  - 10.1101/2022.10.20.22281201
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.10.20.22281201
4099  - http://medrxiv.org/content/early/2022/10/21/2022.10.20.22281201.short
4100  - http://medrxiv.org/content/early/2022/10/21/2022.10.20.22281201.full
AB  - In clinical practice, the co-existence of endometriosis and gastrointestinal symptoms is often observed; however, the factors driving this link remain largely unknown. Here, using large-scale multifaceted data including observational, genetic, and pharmaceutical datasets, we report a positive phenotypic and genetic association of endometriosis with peptic ulcer disease (PUD), gastro-oesophageal reflux disease (GORD), a combined GORD/PUD Medicated (GPM) phenotype and irritable bowel syndrome (IBS), but not with inflammatory bowel disease (IBD). Mendelian randomization analysis identified a causal effect of the GPM phenotype on endometriosis and a bidirectional causal association between endometriosis and IBS. Cross-trait meta-analysis and colocalization along with comprehensive functional annotation confirmed two shared genetic loci (FN1, TACSTD2) for endometriosis with IBS and twelve loci (ETAA1, HOXC4, RERG, SEMA3F, SPAG16, HIST1H2BC, RAB5B, CCKBR and PDE4B) with GORD and PUD. Shared genetic loci may contribute to risk of both endometriosis and digestive disorders through the involvement of DNA damage, estrogen regulated cell-proliferation and inflammation, and barrier dysfunction. Analyses of medication usage identified a higher use of drugs for IBS, GORD and PUD in women diagnosed with endometriosis as well as a higher use of hormone therapies in women diagnosed with IBS, GORD and PUD but not for IBD, which strongly supports the co-occurrence of these conditions and highlights the potential for drug repositioning and caution around drug contraindications in clinical practice. Taken together, the combined evidence robustly suggests a shared disease aetiology and provides important clinical implications for diagnostic and treatment decisions for endometriosis and digestive disorders.WHAT IS ALREADY KNOWN ON THIS TOPIC?Both endometriosis and gastrointestinal disorders affect a large proportion of people worldwide and the co-existence of endometriosis and gastrointestinal symptoms (eg, abnormal pain, bloating, constipation) is often observed in clinical practice.The association of these two diseases was supported but also limited to previous observational evidence which highlights a three-fold increase in the prevalence of irritable bowel syndrome (IBS) in women with endometriosis.Observational study is easily subject to measurement error, confounding and reverse causation. Therefore, it is important to assess the association using multidimensional datasets and more accurate approaches, such as the use of genetic data in a mendelian randomisation framework as well as the analysis from a perspective of medication usage.WHAT THIS STUDY ADDSGenetic risk factors for endometriosis and gastrointestinal disorders, two leading causes of discomfort and chronic pelvic pain, are correlated.Mendelian randomisation analyses supported a causal relationship between genetic predisposition to gastrointestinal disorders (gastro-oesophageal reflux disease (GORD) and peptic ulcer diseases (PUD)) and endometriosis risk, and evidence for a bidirectional causal relationship between endometriosis and IBS, which might explain in part the co-occurrence of these diseases.The identification of shared risk loci highlighted biological pathways that may contribute to the pathogenesis of both diseases, including estrogen regulation and inflammation, as well as potential therapeutic drug targets such as CCKBR and PDE4B.The higher use of drugs for IBS, GORD and PUD in women diagnosed with endometriosis as well as the higher use of hormone therapies in women diagnosed with IBS, GORD and PUD, support the co-occurrence of these conditions and shared disease aetiology but also highlights the potential for drug repositioning and caution around drug contraindications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Health and Medical Research Council of Australia [Project Grants GNT1147846, GNT1105321 and GNT1049472, Investigator Grant 1177194 to G.W.M and Medical Research Future Fund Research Grant MRF1199785 to G.D.M and S.M]. For funding details of the endometriosis meta-analysis please see Sapkota et al., (2017).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank had obtained ethics approval from the North West Multi-centre Research Ethics Committee which covers the UK (approval number: 11/NW/0382) and had obtained informed consent from all participants. The UK Biobank approved an application for use of the data (ID 12505 and 54861) and ethics approval for the analyses was obtained from the Human and Research Ethics Committees (HREC) of the University of Queensland (2020/HE002852). ALSWH was originally approved by the Human and Research Ethics Committees (HREC) of the University of the Newcastle (UoN) in 1995 (Clearance number: H 076 0795) and by The University of Queensland (UQ) in 2004 (reference number: 2004 000 224). The most recent amendment for ALSWH Survey 8 of the 1973-78 cohort was approved by UoN HREC on 8 November 2017 and ratified by UQ HREC on 9 November 2017. Ethical approval for data linkage was obtained from the UoN HREC on 31 January 2012 (Clearance Number: H-2011-0371) and from the UQ HREC on 9 February 2012 (Number: 2012000132).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study includes no data deposited in external repositories.